Otic Pharma Completes Merger with Tokai Pharmaceuticals Company Renamed Novus Therapeutics, Inc; NASDAQ Ticker "NVUS" IRVINE, Calif., May 10, 2017 /PRNewswire/ -- Otic Pharma, Ltd., a pharmaceutical company focusing on the development of ear, nose, and throat (ENT) products, today announced the close of the previously announced combination with Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI, through May 10, 2017). In connection with the previously announced transaction, Tokai changed its name to Novus Therapeutics, Inc. and effected a 1-for-9 reverse split of its common stock. The common stock is expected to commence trading on a post-reverse split basis upon the opening of trading on May 11, 2017 on the NASDAQ Capital Market under the symbol "NVUS." Read More: http://www.prnewswire.com/news-releases/otic-pharma-completes-merger-with-tokai-pharmaceuticals-300454911.html Novus Therapeutics, Inc. Investor Relations Tel: (949) 238-8090 investors@novustherapeutics.com